Zagreb, Croatia, 3rd March 2015 – Fidelta, a Galapagos company, announced today the achievement of a milestone, thereby completing the first phase of an integrated drug discovery project that started in April 2014. Today’s payment remains undisclosed. Furthermore, the next phase of the project has been agreed, which will contribute significantly to Fidelta’s revenues in 2015.
Phil Dudfield, Managing Director, Fidelta commented, “We are excited to be working together with LEO Pharma on this integrated project which aims to develop clinical candidates using Fidelta’s drug discovery expertise.” Thorsten Thormann, Senior Vice President, New Product Discovery, LEO Pharma added, “We are delighted to be working together with Fidelta and to see the rapid progress made in this project. In the first phase of the project, Fidelta has shown a very high scientific standard and has delivered to all our expectations. We are looking forward to continuing a close collaboration into the next phase. The collaboration with Fidelta has proven the value of LEO Pharma’s partnership model, complementing our internal competences by working with world-class external partners. The partnership model with Fidelta aims to break new ground in the field of dermatology in order to bring solutions to the market that can make a real difference to patients’ everyday lives.”
About Fidelta
Fidelta is a fee-for-service, collaborative drug discovery organization that combines expertise in the areas of chemistry, pharmacology, ADME, pharmacokinetics and toxicology. Fidelta offers fully integrated services, as well as flexible stand-alone solutions for projects in discovery and early pre-clinical development. Fidelta has developed a new macrocyclic drug discovery platform, FideltaMacro.TM Fidelta’s objective is to deliver efficacious, safe and differentiated pre-clinical candidates to its clients. For more information, visit www.fidelta.eu. For more information about parent company Galapagos, visit www.glpg.com.
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide. For more information, visit www.leo-pharma.com.
Contact:
Fidelta d.o.o.
Adrijana Vinter, Business Development Director
Tel: +385 1 8886395
fidelta@glpg.com
Help employers find you! Check out all the jobs and post your resume.
